Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Man Group plc

Man Group plc boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 878.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,426 shares of the company's stock after buying an additional 127,875 shares during the quarter. Man Group plc owned approximately 0.11% of Vaxcyte worth $11,659,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of PCVX. CIBC Asset Management Inc boosted its stake in shares of Vaxcyte by 5.5% during the fourth quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock worth $271,000 after buying an additional 171 shares during the period. Bridgefront Capital LLC boosted its stake in shares of Vaxcyte by 4.2% during the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after buying an additional 172 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the period. Catalyst Funds Management Pty Ltd boosted its stake in shares of Vaxcyte by 1.7% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after buying an additional 300 shares during the period. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

Vaxcyte stock traded down $1.41 during mid-day trading on Friday, reaching $32.54. The company had a trading volume of 1,763,863 shares, compared to its average volume of 1,371,448. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06. The company has a market capitalization of $4.20 billion, a P/E ratio of -7.07 and a beta of 1.27. The stock's 50-day simple moving average is $38.53 and its 200-day simple moving average is $69.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the prior year, the firm earned ($0.85) EPS. On average, equities analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. This trade represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PCVX has been the subject of several recent research reports. Bank of America decreased their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating for the company. Needham & Company LLC reiterated a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, The Goldman Sachs Group reduced their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.